Articles
Today's Biomanufacturing Model Is Broken
December 3, 2010
•White Paper: Today's Biomanufacturing Model Is Broken
Fixing the model will open new doors
Modern biopharmaceutical production is burdened with problems very different from what the traditional pharma industry faced during its development. Where the pharmaceutical industry was built on the backs of blockbuster drugs, biopharm will grow as a collection of smaller, targeted treatments.
With more than 500 biopharmaceuticals in various stages of clinical development, the market is on the precipice of bursting with products that will outstrip available manufacturing capacity. Many biotherapeutics will hit a dead-end due to the lack of economical production options.
Add the emerging markets for biosimilars (more than $20 Billion in pending patent expirations), vaccines, and the exploding need for pandemic and bioterror response capacity, and the biopharm industry faces an overwhelming production crisis. Without dramatic innovation in manufacturing strategies and technologies, the industry and the public it serves are in serious trouble.
Click Here To Download:•White Paper: Today's Biomanufacturing Model Is Broken
SOURCE: Xcellerex
